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Abstract
Although most patients with early-stage
nasopharyngeal carcinoma (NPC) can be cured
by radiotherapy, there is a high recurrence rate
in patients with advanced NPC. We attempted to
identify proteomic patterns in sera for predicting
tumor recurrence. Pretreatment sera were col-
lected from 64 NPC patients with complete
remission after radiotherapy. Serum proteins
were profiled by SELDI ProteinChip technology,
and correlated with local/distant recurrence. 
Forty proteomic features were significantly dif-
ferent between the patient groups with and with-
out tumor recurrence. Univariate analyses showed
that 32 of them were significantly associated with
time to first recurrence. Multivariate Cox-regres-
sion analyses identified International Union
Against Cancer (UICC) stage and two proteomic
features with mass/charge (m/z) values of 8808
and 6626 as independent prognostic indicators for
tumor recurrence. The hazard ratios were 2.0 (95%
confidence interval, CI 1.3–3.2) and 0.79 (95% CI
0.64–0.96) for a double of peak intensity of pro-
teomic feature m/z 8808 and m/z 6626, respec-
tively. These two proteomic features were also
independent prognosticators for overall survival.
A decision tree was constructed to predict the
tumor recurrence by using UICC stage, proteomic
feature m/z 8808, and proteomic feature m/z
6626, and evaluated by Leave-One-Out cross-
validation. Kaplan-Meier analysis confirmed that
the decision tree could predict both recurrence-
free survival and overall survival. The positive
and negative predictive values for tumor recur-
rence within 4 yr were 74 and 89%, respectively. 
A serum proteomic pattern comprising fea-
tures m/z 8808 and m/z 6626 is a potential sur-
rogate marker of disease recurrence after
radiotherapy in NPC. 
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Introduction
Nasopharyngeal carcinoma (NPC) is an
endemic disease in Southern China (1). Over
60% of NPC patients present with advanced
International Union Against Cancer (UICC)
stage (stages 3 and 4) disease. Primary treat-
ment for non-metastatic NPC is radical exter-
nal radiotherapy (RT). Most patients with
early-stage NPC will achieve a complete clin-
ical remission after RT with or without con-
current chemotherapy. However, patients
with locoregionally advanced disease (UICC
stages 3 and 4) have significant recurrence
rates, 30–40%, of both local recurrences and
particularly distant metastases following RT
alone (2). Once the patients have developed
local recurrences or distant metastases, the
treatment outcome is poor. If such patients
with a high risk of recurrence were identi-
fied, more intensive therapy could be pro-
vided to improve the treatment outcomes,
and those with a lower risk of recurrence
could be spared from such a potentially toxic
treatment.
Surface-enhanced laser desorption/ion-
ization (SELDI) ProteinChip technology is a
recent proteomic tool that has been applied
to the discovery of diagnostic proteomic pat-
terns for various diseases including cancers
and infectious diseases (3–6). Apart from
application in cancer diagnosis, recent stud-
ies have strongly suggested that the SELDI
ProteinChip technology is also useful in
discovering proteomic pattern for monitor-
ing recurrence of NPC (7) and predicting
treatment response in cancer patients (8). In
the present study we aimed to identify
serum proteomic features by the SELDI
ProteinChip technology for predicting




This study was approved by the Ethics
Committee of the Chinese University of
Hong Kong. Pretreatment serum samples,
that were stored at –70ºC, were archived for
this retrospective study. The samples were
from 64 patients with newly diagnosed
undifferentiated NPC (World Health Organi-
zation type III histology) admitted between
October 1995 and July 1997 at the
Department of Clinical Oncology, Prince of
Wales hospital, Hong Kong. Disease staging
was based on the UICC 1997 (5th Edition)
classification, and all patients underwent
pretreatment evaluation with physical exam-
ination, chest X-ray, contrast-enhanced com-
puted tomography of the nasopharynx, and
nasopharyngoscopy. Patients with UICC
tumor stage (T) 3 to 4 and/or node stage (N)
2–3 disease also had baseline bone scan and
abdominal ultrasound (US). External RT was
administered to all patients according to the
techniques described by Ho et al. (1). Stan-
dard fractionated RT at 2 gy/d was delivered
to the primary tumor and nodes to a total
dose of 66–70 gy. Twelve patients also
received concurrent cisplatin and RT (CT-RT)
as part of a clinical trial, at a dose of 40
mg/m2 over a weekly schedule (11). All 64
patients achieved complete remission by 4–6
wk after completion of RT, and were fol-
lowed thereafter every 8–12 wk with physi-
cal examination and nasopharyngoscopy
until February 3, 2001. Suspected disease
recurrence were investigated radiologically
with CT, US or magnetic resonance imaging
(MRI), and confirmed histologically where
possible.
Serum Proteomic Profiling
Serum samples were subjected to the
SELDI ProteinChip analysis to obtain a quan-
titative proteomic profile with molecular mass
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ranging from 0.9 to 250 kDa, as previously
described (4,5). The intra- and inter-assay
coefficient of variations of the peak intensities
were less than 15%. All samples were ana-
lyzed blindly without knowledge of the
clinical information. It was performed with
two types of ProteinChip Arrays, H50 and
CM10. For the hydrophobic H50 ProteinChip
assay, the H50 ProteinChip arrays were pre-
equilibrated with 150 L of 0.1% trifluo-
roacetic acid (TFA) solution, and subsequently
with 150 L of sample diluent (phosphate-
buffered saline containing 0.1% TFA) for 5
min. Five microliters of 20-fold diluted serum
was added to the ProteinChip arrays in
duplicate. For the weak cation exchange
CM10 ProteinChip assay, 2 L of the serum
sample were denatured by adding 4 L of U9
solution (9 M urea, 2% CHAPS, 50 mM Tris-
HCl, pH 9.0), and subsequently diluted with
34 L of T4 solution (50 mM sodium acetate,
0.1% Trition X-100, pH 4.0) to result in a final
dilution of 20-fold. CM10 ProteinChip arrays
were pre-equilibrated twice with 150 L of
the binding buffer for 5 min. Then 5 L of the
diluted sample were applied to the Pro-
teinChip array in duplicate. For both H50
and CM10 ProteinChip assays, serum proteins
were allowed to bind to the arrays with
shaking at room temperature for 90 min. After
the incubation, the H50 and CM10 Pro-
teinChip arrays were washed five times with
0.1% TFA solution and T4 solution, respec-
tively. After rinsing with deionized water and
air-drying, sinapinic acid matrix in 50% ace-
tonitrile and 0.5% TFA was added to each
array. The ProteinChip Arrays were read on a
ProteinChip PBS II reader of the ProteinChip
Biomarker System to measure the masses and
intensities of the protein peaks (Ciphergen
Biosystems). The common peaks among the
SELDI mass spectra were identified and
quantified using the Biomarker Wizard soft-
ware (Ciphergen Biosystem). The peak inten-
sities were normalized with the total ion
current, and subsequently with the total peak
intensities. Before data mining, the normal-
ized peak intensities of the duplicate mea-
surements were averaged, followed by log2
transformation.
Identification of Recurrence-Associated
Proteomic Features by Statistical
Analysis 
To avoid identification of proteomic features
that might be only associated with the investi-
gated patients, but not recurrence itself, recur-
rence-associated proteomic features were the
SELDI proteomic features that fulfilled three cri-
teria: (1) normalized peak intensity was statisti-
cally significantly different between the patients
with and without tumor recurrence; (2) the pro-
teomic feature was statistically significantly
associated with the time to first recurrence as
shown by univariate analysis; and (3) the pro-
teomic feature was an independent prognostic
indicator as shown by multivariate analysis.
Statistical analyses were performed by SPSS
program release 10.0 (SPSS Inc., Chicago, IL).
To achieve a higher stringency of the statistical
tests, for univariate statistical analyses a null
hypothesis was rejected when a two-sided p-
value was less than 0.025. The difference in a
proteomic feature between the patient groups
with and without local/distant recurrences
was evaluated using the Mann-Whitney U-
test. Recurrence-free survival was defined
from the date of completion of radiotherapy
to the date of first local/distant recurrence or
censored at the date of last follow up. Overall
survival was defined from the date of con-
firmed diagnosis to the date of death or last
follow-up. Univariate Cox-regression analysis
was applied to evaluate the associations of the
proteomic features with time to first local/dis-
tant recurrence. A stepwise Cox proportional
hazard model was used to examine the asso-
ciation of various prognostic factors, including
the proteomic features, age, sex, T stage, N
stage, and UICC overall stage.
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Construction and Evaluation of Decision
Tree for Predicting Recurrence
A Classification and Regression Tree algo-
rithm (CART) model as implemented in S-PLUS
(Insightful, Seattle, WA) (9) was trained to
construct a decision tree for predicting NPC
patients with or without local/distant recur-
rences, as previously described by Poon et al.
(10) and Markey et al. (11). Independent prog-
nostic indicators identified by the multivariate
Cox-regression analysis were used as input
variables for generating the tree model. To
prevent over-fitting, the decision tree was
pruned to reduce terminal branches to 5 or
fewer. The purpose of building a decision tree
is to provide a parsimonious, and clinically
easy-to-use, prediction system. 
The performance of the resulted decision tree
model was evaluated by Leave-One-Out cross-
validation (11,13). Briefly, a CART model was
trained on (64–1) cases, and the trained model
was then used to test the case that had been left
out. This process was repeated 64 times until
every case in the dataset had been used once as
an unseen independent test case. The results
from the 64 test cases were used to estimate the
classifier’s prediction performance. The prog-
nostic significance of the model on recurrence-
free survival and overall survival was tested by
the univariate Kaplan-Meier method and Log
rank test. To assess the performance of the deci-
sion tree as a prediction tool for important clin-
ical outcomes, the positive and negative
predictive values of the model was calculated
using standard formulae. 
Results
Overall Clinical Outcome
The patient characteristics of the 64 patients
are listed in Table 1. Data collected up to
February 3, 2001 was included in the survival
analysis. The median follow-up was 3.9 yr. At
the time of last follow-up, 14 patients devel-
oped local recurrences, and 13 developed
distant metastases. Three had both local and
distant metastases, so that there was a total of
24 recurrence events. Thirty-five patients were
alive without disease; one patient was alive
with disease. There were 28 deaths, 23 of
which were related to tumor recurrence. 
Serum Proteomic Features Associated
With Patients With Tumor Recurrence
A total of 690 proteomic features were
found among the pretreatment serum sam-
ples, 331 by the hydrophobic H50 ProteinChip
arrays and 359 by the weak cation ion
exchange CM10 ProteinChip arrays. To search
for proteins/polypeptides significantly associ-
ated with recurrence, we performed Mann-
Whitney U-test to compare proteomic features
between cases with and without local/distant
recurrence. Relative levels of 22 and 18 fea-
tures were found to be significantly higher
and lower in the group with tumor recurrence,
respectively (all p-values < 0.025). Univariate
Cox-regression analysis showed that 32 of
these 40 proteomic features were significantly
associated with time to first tumor recurrence
(all p-values < 0.025). 
Multivariate Analyses of Recurrence-Free
Survival and Overall Survival
Multivariate Cox-regression analysis was
performed to examine whether the proteomic
features could provide prognostic information
in additional to the traditional TNM staging
system. The multivariate Cox-regression model
showed that among the 32 significant pro-
teomic features, proteomic features with
mass/charge (m/z) values of 8808 (range
8796–8821) (p = 0.002) and 6626 (range
6623–6629) (p = 0.02), and overall UICC stage
(p = 0.003) were independent prognostic indi-
cators of tumor recurrence. Sex, age, T stage,
and N stage were not statistically significant,
and excluded in the model. The multivariate
Cox-regression model of recurrence-free
survival revealed hazard ratios of 2.0 (95%
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confidence interval, CI 1.3–3.2) for a double of
the peak intensity of the proteomic feature
m/z 8808, 0.79 (95% CI 0.64–0.96) for a double
of the peak intensity of the proteomic feature
m/z 6626, and 2.2 (95% CI 1.3–3.7) for a UICC
overall stage increment. The multivariate Cox-
regression analysis also showed that proteomic
feature m/z 8808 (p = 0.046), proteomic feature
m/z 6626 (p = 0.013), and UICC overall stage
(p = 0.001) were statistically significantly asso-
ciated with overall survival. Therefore, our
data indicated that higher serum level of pro-
teomic feature m/z 8808 and lower serum
level of proteomic feature m/z 6626 were sig-
nificantly associated with higher rate of tumor
recurrence and poor overall survival, and were
independent predictors in additional to over-
all UICC stage (Fig. 1). 
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Fig. 1. Higher peak intensity of proteomic feature mass/charge (m/z) 8808 was significantly associated with higher
rate of tumor recurrence (A) and poor overall survival (B), whereas lower peak intensity of proteomic feature
m/z 6626 was significantly associated with higher rate of tumor recurrence (C), and poor overall survival (D).
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Decision Tree for Predicting Tumor
Recurrence
Figure 2 indicates a pruned decision tree
resulted from CART modeling for predicting
NPC patients with and without tumor recur-
rences by using the UICC stage and proteomic
features m/z 8808 and m/z 6626. The perfor-
mance of the decision tree model was evaluated
by Leave-One-Out cross-validation (Fig. 2). The
cross-validation result showed that this decision
tree correctly predicted 20 of 24 patients (83%)
with local recurrences and/or distant metastases,
and 33 of 40 (83%) of patients without recur-
rence, resulting in an overall accuracy of 83%.
This decision tree correctly identified 11 of 13
cases (85%) with distant metastases, and 10 of 14
cases (71%) with local recurrences. Kaplan-Meier
analysis showed that the decision tree could
predict both recurrence-free survival (p < 0.00005;
log-rank statistics = 34.1), and overall survival
(p < 0.00005; log-rank statistics = 27.0) (Fig. 3). 
To assess the performance of the decision
tree as a prediction tool for important clinical
outcomes, we evaluated the positive and neg-
ative predictive values for tumor recurrence
within 4 yr after achieving complete remis-
sion. The positive predictive value was 74%,
and the negative predictive value was 89%. 
Discussion
About 80% of patients with early-stage
(UICC stage I and II) NPC can be cured of
their disease with standard radical RT. How-
ever in patients with more advanced disease
stages (UICC stage III and IV), recurrence is
common and, consequently, 5-yr survival rates
are only 45–60%. Recent studies have demon-
strated an improvement of progression-free
survival with concurrent cisplatin and RT
compared with RT alone, and the improve-
ment was statistically significant in patients
with advanced disease (12). Unfortunately
concurrent cisplatin and RT resulted in con-
siderable toxicity. Probably more intensive
therapy after concurrent chemoradiation can
further improve the treatment results (14), but
such strategy will require better selection of
patients to confine treatment to those who will
benefit most, and to avoid toxic therapy in
those who are likely to be already cured. 
Previously we reported that level of post-
treatment circulating Epstein-Barr virus (EBV)
DNA was an independent prognostic indica-
tor for distant metastasis as shown by multi-
variate Cox-regression analysis (15). However,
neither the level of pretreatment EBV DNA
nor the level of post-treatment EBV DNA was
statistically associated with local recurrence in

























Local Recurrences after RT, No. (%) 14 (22%)
Distant Metastases after RT, No. (%) 13 (20%)
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the multivariate analysis. It appears that other
serum/plasma markers are needed for pre-
dicting local recurrence. 
In this study, we demonstrated that a
unique proteomic pattern was present in
pretreatment sera of the NPC patients who
later had local/distant recurrence within 4 yr.
Multivariate Cox-regression analysis revealed
that two proteomic features with molecular
weight of 6626 and 8808 Daltons were statis-
tically significantly associated with the time
to first local/distant recurrence. The multi-
variate analysis result also indicates that these
two proteomic features provide prognostic
information in additional to the traditional
TNM staging system. As inclusion of the pro-
teomic features did not lead to an exclusion of
overall UICC stage in the Cox-regression
model, this indicates that overall UICC stage
provides some prognostic information that the
proteomic features do not have. Therefore the
two serum proteomic features and overall
UICC stage are complementary to each other
in predicting tumor recurrence after RT. 
Furthermore, the decision tree, based on the
peak intensities of these two proteomic features
and overall UICC stage, demonstrated high
positive and negative predictive values, as
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Fig. 2.The pruned decision tree generated from International Union Against Cancer (UICC) overall stage, serum
levels (log2 normalized peak intensities) of proteomic feature m/z 8808 and proteomic features m/z 6626 for pre-
dicting recurrence after radiotherapy (RT) in nasopharyngeal carcinoma (NPC). The decision tree divides patients
into 5 groups. Two groups (R1 and R2) are for the patients with tumor recurrence, whereas three groups (CR1,
CR2 and CR3) are for the patients without recurrence in 4 yr after RT. The Leave-One-Out cross-validation
result (No.) of the patients without recurrence (recurrence free, RF) and with local recurrence (LR) and/or
distant metastasis (DM) is bracketed.The wrongly predicted cases were italic and asterisked (*).
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showed by the Leave-One-Out cross-validation.
Although the decision tree could not differenti-
ate local recurrence from distant metastasis, the
decision tree correctly predicted patients with
local recurrence and patients with distant
metastasis at similar sensitivity. Our results sug-
gest that the proteomic pattern comprising the
6626 and 8808 Daltons proteomic features is a
potential surrogate marker for predicting not
only distant metastasis, but also local recurrence
in NPC patients after curative RT. It is impor-
tant to emphasize that the current study was
exploratory in nature. Further studies are
needed to validate the use of this predictive
model in NPC patients in a prospective manner,
or at least to be validated with another retro-
spective study of larger sample size. It will be
also invaluable to investigate whether combined
use of circulating EBV DNA and proteomic pat-
tern could further the predictive values for
local/distant recurrence, and to investigate the
protein identity of these two proteomic features.
Nevertheless, because each protein has a unique
m/z value, even without knowing their protein
identities, they can be unambiguously detected
and quantified in patient sera.
Recently, it has been suggested that the
findings of studies employing the SELDI Pro-
teinChip technology could be biased by arti-
facts related to the nature of the clinical
samples used, the sample storage conditions,
the experimental details, the mass spectromet-
ric instruments, and/or bioinformatic analyses
(16,17). In the present study, various preven-
tive measures have been carried out to avoid
generation of biased results, as previously
described by Poon et al. (5,6). First, all the
serum samples were collected and processed
within the same clinical and laboratory set-
tings. Second, to ensure the quality of the
serum samples, all samples were processed
within 1 h after the blood taking, and the
serum samples were stored at –70ºC before
analysis. Third, all samples were analyzed
blindly without knowledge of the recurrence
status. Fourth, stringent criteria were used to
define a proteomic feature as a potential prog-
nostic indicator of tumor recurrence in this
study as described in the statistical methods. 
In conclusion, the present study demon-
strated that a unique serum proteomic pattern is
present in the pretreatment sera of NPC patients
who subsequently developed local/distant
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Fig. 3. (A) Recurrence-free survival analysis and (B)
overall survival analysis of the Leave-One-Out cross-
validation result of the decision tree (DT) in pre-
dicting patients with (DT groups: R1, R2) or without
(DT groups: CR1, CR2, CR3) local/distant recurrence
after curative radiotherapy.
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recurrences following RT. The pattern identified
by the SELDI ProteinChip technology together
with UICC stage could be used to construct a
decision tree in predicting recurrence with high
positive and negative predictive values.
Acknowledgments
This work was supported by a Strategic
Research Area Grant from the Chinese Uni-
versity of Hong Kong and a Central Allocation
Grant from the University Grants Committee
of Hong Kong.
References
1. Ho, J.H.C. (1978) An epidemiologic and clini-
cal study of nasopharyngeal carcinoma. Int. J.
Radiat. Oncol. Bio. Phys. 4:183–205.
2. Teo, P.M., Yu, P., Lee, W.Y., Leung, S.F., Kwan,
W.H., Yu, K.H., et al. (1996) Significant prog-
nosticators after primary radiotherapy in 903
nondisseminated nasopharyngeal carcinoma
evaluated by computer tomography. Int. J.
Radiat. Oncol. Biol. Phys. 36:291–304.
3. Petricoin III, E.F., Ardekani, A.M., Hitt, A.B.,
Levine, P.J., Fusaro, V.A., Steinberg, S.M., et al.
(2002) Use of proteomic patterns in serum to
identify ovarian cancer. Lancet 359:572–577.
4. Poon, T.C.W., Yip, T.T., Chan, A.T.C., Yip, C.,
Yip, V., Mok, T.S.K., et al. (2003) Comprehen-
sive proteomic profiling identifies serum
proteomic signatures for detection of hepato-
cellular carcinoma and its subtypes. Clin.
Chem. 49:752–760.
5. Poon, T.C.W., Chan, K.C.A., Ng, P.C., Chiu,
R.W.K., Ang, I.L., Tong, Y.K., et al. (2004) Serial
analysis of plasma proteomic signatures in
pediatric patients with severe acute respira-
tory syndrome and correlation with viral load.
Clin. Chem. 50:1452–1455.
6. Poon, T.C.W., Hui, A.Y., Chan, H.L.Y., Ang,
I.L., Chow, S.M., Wong, N., et al. (2005) Pre-
diction of liver fibrosis and cirrhosis in chronic
Hepatitis B Infection by serum proteomic Fin-
gerprinting: a pilot study. Clin Chem. in press.
7. Cho, W.C., Yipm, T.T., Yip, C., Yip, V., Thu-
lasiraman, V., Ngan, R.K.C., et al. (2004) Iden-
tification of serum amyloid a protein as a
potentially useful biomarker to monitor
relapse of nasopharyngeal cancer by serum
proteomic profiling. Clin. Cancer Res. 10:43–52.
8. Xiao, Z., Luke, B.T., Izmirlian, G., Umar, A.,
Lynch, P.M., Phillips, R.K., et al. (2004)
Serum proteomic profiles suggest celecoxib-
modulated targets and response predictors.
Cancer Res. 64:2904–2909.
9. Breiman, L., Friedman, J.H., Olshen, R.A., and
Stone, C.J. (1984) Classification and regression
trees. In The Wadsworth Statistics/Probability
Series. (Bickel, P., Cleveland, W., and Dudley,
R., eds.), Belmont: Wadsworth International
Group. 
10. Poon, T.C.W., Chan, A.T.C., Zee, B., Ho, S.K.W.,
Mok, T.S.K., Leung, T.W.T., et al. (2001) Appli-
cation of classification tree and neural network
algorithm to the identification of serological
liver marker profiles in the diagnosis of hepa-
tocellular carcinoma. Oncology 61:275–283.
11. Markey, M.K., Tourassi, G.D., and Floyd Jr,
C.E. (2003) Decision tree classification of pro-
teins identified by mass spectrometry of blood
serum samples from people with and without
lung cancer. Proteomics 3:1678–1679.
12. Chan, A.T.C., Teo, P.M.L., Nagan, R.K., Leung,
T.W., Lau, W.H., Zee, B., et al. (2002) Concur-
rent chemotherapy-radiotherapy compared
with radiotherapy alone in locoregionally
advanced nasopharyngeal carcinoma: pro-
gression free survival analysis of a phase III
randomized trial. J. Clin. Oncol. 20:2038–2044.
13. Radmacher, M.D., McShane, L.M., and Simon,
R. (2002) A paradigm for class prediction
using gene expression profiles. J. Comput.
Biol. 9:505–511.
14. Al-Sarraf, M., LeBlanc, M., Giri, P.G., Fu, K.K.,
Cooper, J., Vuong, T., et al. (1998) Chemora-
diotherapy versus radiotherapy in patients
with advanced nasopharyngeal cancer: phase
III randomized intergroup study 0099. J. Clin.
Oncol. 16:1310–1317.
15. Chan, A.T.C., Lo, Y.M.D., Zee, B., Chan, L.Y.S.,
Ma, B.B.Y., Leung, S.F., et al. (2002) Plasma
Epstein-Barr virus DNA and residual disease
after radiotherapy after radiotherapy for
undifferentiated carcinoma. J. Natl. Cancer.
Inst. 94:1614–1619.
16. Diamandis, E.P. (2003) Proteomic patterns in
biological fluids: do they represent the future
of diagnostics? Clin. Chem. 49:1272–1275.
17. Diamandis, E.P. (2004) Analysis of serum
proteomic patterns for early cancer diagnosis:
drawing attention to potential problems. J.
Natl. Cancer Inst. 96:353–256.
Serum Proteomic Pattern Predicts NPC Recurrence ______________________________________________ 373
